Infliximab drug data and news

Infliximab drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.

Generic name Infliximab
Brand Names/Synonyms Ig gamma-1 chain C region; Remicade (Centocor Inc)
Indication For treatment of Crohn's disease, psoriasis, rheumatoid arthitis and ankylosing spondylitis
Sponsored links
Description Tumor necrosis factor (TNF-alpha) binding antibody (chimeric IgG1). It is composed of human constant and murine variable regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion
Pharmacology Used in the treatment of auto-immune disorders such as Crohn'€™s disease and rheumatoid arthritis. Infliximab binds to tumor necrosis factor alpha (TNFa) and inhibits binding of TNFa with its receptors. This reduces production of pro-inflammatory cytokines such as interleukins (IL) 1 and 6. This also limits leukocyte migration and expression of adhesion molecules by endothelial cells and leukocytes. Infliximab also limits the activation of neutrophil and eosinophil functional activity, reduces production of tissue degrading enzymes produced by synoviocytes and/or chondrocytes. Infliximab decreases synovitis and joint erosions in collagen-induced arthritis and allows eroded joints to heal.
Mechanism Of Action Infliximab neutralizes the biological activity of TNFa by binding with high affinity to the soluble and transmembrane forms of TNFa and inhibits binding of TNFa with its receptors. Infliximab does not neutralize TNFb (lymphotoxin a), a related cytokine that utilizes the same receptors as TNFa
Infliximab News
(When available)

Analysis: Remicade works for psorasis  07 Mar 2006
SAN FRANCISCO, March 6 (UPI) -- Remicade (infliximab) -- a drug already approved by the Food and Drug Administration for the treatment of rheumatoid arthritis ... - United Press International

Infliximab for Crohn’s Disease Not Associated with Increased ...  Feb 8, 2006
According to a recent article published in the journal Gut, the agent infliximab that is commonly used for the treatment of Crohn’s disease does not appear ... - Cancer Consultants (press release),

REMICADE(R) Phase 3 Data Show Rapid and Significant Improvement ...  Mar 3, 2006
SAN FRANCISCO, March 3 /PRNewswire/ -- Phase 3 data show treatment with REMICADE(R) (infliximab) resulted in rapid, significant improvement and long- term ... - PR Newswire (press release),

REMICADE(R) Phase 3 Data Show Rapid and Significant Improvement ...  Mar 3, 2006
Level, Sustained Response with Maintenance Therapy SAN FRANCISCO, March 3 /PRNewswire/ -- Phase 3 data show treatment with REMICADE(R) (infliximab) resulted in ... - PR Newswire (press release),

FDA Approves Rituxan for Refractory Rheumatoid Arthritis  Mar 1, 2006
...in combination with methotrexate in patients with moderate-to-severe RA that has been refractory to treatment with Enbrel (etanercept) or Remicade (infliximab ... - MedPage Today,

Genentech/Biogen Idec: Rituxan further expands its options  Mar 2, 2006
...treatments (DMARDs), followed by the more expensive biologics such as Amgen's Enbrel (etanercept) or Johnson & Johnson's Remicade (infliximab), which are both ... - Pharmaceutical Business Review

FDA clears Rituxan for rheumatoid arthritis  Mar 1, 2006
...in patients who have not responded to biologic therapy based on tumour necrosis factor blockers, namely Centocor's Remicade (infliximab), Amgen/Wyeth's Enbrel ... - Pharma Times (subscription),

Genentech, Biogen Idec Gain Approval Of Rituxan In RA  Mar 1, 2006
TNF antagonist therapies such as Enbrel (etanercept, from Amgen Inc.), Humira (adalimumab, from Abbott Laboratories) and Remicade (infliximab, from Johnson & ... - BioWorld Online (subscription),

Three-year studies on a novel therapy for rheumatoid arthritis ...  Feb 22, 2006
England Journal of Medicine is that abatacept works very well even in those patients who have failed on other biologic agents, such as etanercept and infliximab ... - Canada NewsWire (press release),

BAMBOO SPINE, A SPECIAL KIND OF ARTHRITIS  Feb 25, 2006
Pamidronate, a medicine used for osteoporosis, has also been found effective for AS; so have two newer drugs, infliximab and etanercept. DEAR DR. ... - Charlotte Sun-Herald,

Rheumatic Diseases Remain a Significant Cause of Chronic Illness ...  Feb 22, 2006
Juvenile arthritis is the next indication due for approval for blockbuster biologic therapies Remicade (infliximab) and Humira (adalimumab). ... - Business Wire (press release),

Better Fix For Rheumatoid Arthritis  Feb 16, 2006
...which contribute to inflammation. Examples are etanercept, infliximab, adalimumab and anakinra. • Protein-A Immunoadsorption Therapy ... - WFtv.com,

American Journal of Clinical Nutrition, Vol. 83, No. 2, 475S-483S ...  Feb 17, 2006
...shown by the fact that recombinant drugs that block the activity of either TNF- [etanercept (Enbrel; Amgen, Thousand Oaks, CA); infliximab (Remicade; Centocor ... - Am J Clin Nutr (subscription),

Inflammatory Diseases - Both Chronic Diseases, Such as Rheumatoid ...  Feb 1, 2006
CD). Nearly all sales were generated by the three available anti-TNF-a agents: etanercept, infliximab, and adalimumab. -- Twenty ... - Genetic Engineering News,

Novel drug treatments help against gout and colitis  Jan 31, 2006
Infliximab, sold under the brand name Remicade for arthritis and Crohn's disease, was shown to sharply reduce bloody diarrhea, abdominal cramps and other ... - Montreal Gazette,

Dosage Forms POWDER FOR SOLUTION
Drug_Category Immunomodulatory Agents; Immunosuppresants; unclassified therapeutic agents (92:00.00)
Absorption Not Available
Interactions Not Available
Toxicity Not Available
Organisms Affected Humans and other mammals
Chemical IUPAC Name Chimeric mouse/human anti-TNF-alpha antibody (cA2)
Chemical Formula C6428H9912N1694O1987S46 >Mouse-Human chimeric chain 1 Anti-TNF alpha VL >Mouse-Human chimeric chain 2 Anti-TNF alpha VH >Mouse-Human chimeric chain 2 Anti-TNF alpha VL
Molecular Weight 144190.3
Smiles String Not Available
Melting Point 61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).
Water Solubility Not Available
State Transparent, slightly viscous, aqueous liquid
LogP/Hphobicity -0.441
Isoelectric Point 8.25
Biotransformation Most likely removed by opsonization via the reticuloendothelial system when bound to T lymphocytes, or by human antimurine antibody production
Half Life 9.5 days
Protein Binding [%] Not Available
RxList Link RXlist
Sponsored links
Drug Reference http://www.drugs.com/cons/Infliximab.html
http://www.rxlist.com/cgi/generic3/infliximab.htm
Drug Type Approved Drug
Accession No BIOD00004
CAS Registry Number 331731-18-1
KEGG Compound ID Not Available
PubChem ID Not Available
PharmGKB ID PA452639
SwissProt ID IGHG1_HUMAN (P01857)
GenBank ID J00228
Drug ID Number [DIN] 2244016

Home | About | Cancers | Treatment | Medications
Copyright onconews.org 2005.
All Rights Reserved.
Google
 
Web onconews.org